Back to results
US 8,044,097 B2Granted
Chroman derivatives
AssigneeAmpere Life Sciences, Inc.
InventorsBing Wang, Jian Chen
Life of this patent
Estimating the term…
Abstract
The invention relates to novel chroman derivatives, stereoisomers and pharmaceutically acceptable salts of Formula I wherein the substituents are as defined in the specification. They are useful in the treatment of disorders mediated by lipoxygenase, such as immune diseases, respiratory diseases and cardiovascular diseases, as well as in the treatment of neurodegenerative disorders and/or mitochondria) disorders. They are also useful in the manufacture of pharmaceutical formulations for the treatment of such conditions.
Claims11
A compound represented by Formula I
- wherein:
- -A-B— is —CH2—CH2—, —CH═CH—, —CH2—O—, or —CH2—S—;
- n is 0;
- R1 is C1-4 alkyl;
- R2 is C1-4 alkyl;
- R3 is
- cycloalkyl, aryl, or saturated, partially unsaturated or unsaturated heterocyclyl, all rings optionally substituted with one or more substituents selected from alkyl, haloalkyl, hydroxy, alkoxy, halogen, oxo, cyano, nitro, amino, —SO2NR2, and —C(O)OR, with the proviso that the heterocyclyl is not substituted or unsubstituted 4,5-dihydro-isoxazol-3-yl or substituted or unsubstituted chroman;
- or
- haloalkenyl;
- R4 is hydrogen, optionally substituted C1-4 alkyl, C2-12 alkenyl, hydroxyalkyl, acyl, glucoside, phosphoryl, phosphoryloxyalkyl, carboxyalkylcarbonyl, aminoalkylcarbonyl, or alkylketocarbonyl;
- R5 and R6 are independently of each other C1-6 alkyl, C2-12 alkenyl, or halogen;
- and
- R is hydrogen or C1-4 alkyl;
- or
- single stereoisomers, mixtures of stereoisomers, or pharmaceutically acceptable salts thereof.
12 more elements
Dependencies are inferred from the claim text.